Circle Pharma Features Preclinical Results of CID-078 at the WCLC 2024
Shots:
- Circle Pharma has highlighted the non-clinical data of CID-078 (cyclin A/B RxL inhibitor) as a poster at WCLC 2024
- CID-078 showed tumor regressions in preclinical models of SCLC & NSCLC. Tumor growth inhibition was also observed in models with high E2F target and G2M checkpoint scores as well as increased E2F1, cyclin B1 & ESPL1 levels. The activity aligns with the proposed mechanism of cyclin A/B RxL inhibition, causing DNA damage
- These results can form the basis of CID-078’s advancement to P-I study as monotx. in patients with lung cancer
Ref: Businesswire | Image: Circle Pharma
Related News:- Grit Biotechnology Reports the US FDA’s IND Approval of GT201 for Treating Advanced Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
